Chronic Myelogenous Leukemia (CML) Pathways

Patient Name:_____ Date of Birth:_____

Member Number: _____ Treatment Start Date:_____

Pathology:_____ **Stage**:_____

Line of Therapy: __1st Line __2nd Line __3rd Line __3rd Line+ **ECOG Performance Status**:_____ ICD-10 Code:_____

Biomarkers/Characteristics: (select all that apply)

CML Phase: __ Chronic Phase __ Accelerated Phase __ Lymphoid Blast Phase __ Myeloid Blast Phase __ Not Reported

Imatinib resistant or intolerant: __ Yes __ No Philadelphia chromosome: __ Positive __ Negative

T315I: __ Positive __ Negative Mutation: ____V299L ___T3151

First Line of Therapy (1st Line) | Low Risk Disease

___Imatinib (Gleevec)

First Line of Therapy (1st Line) | Intermediate or High Risk Disease*

___Dasatinib (Sprycel)

___Imatinib (Gleevec)

___Nilotinib (Tasigna)

Second Line of Therapy (2nd Line) | Following Treatment Failure, Suboptimal Response† , or Intolerance to 1st Line

___Bosutinib (Bosulif)

___Dasatinib (Sprycel)

___Nilotinib (Tasigna)

___Ponatinib (Iclusig)‡

Third Line of Therapy (3rd Line)

___Ponatinib (Iclusig)

*For patients with intermediate or high risk disease based on Sokal or Hasford score:

- Sokal: Intermediate Risk=0.8-1.2; High Risk>1.2
- Hasford: Intermediate Risk=781-1480; High Risk>1480

†Defined as lack of complete hematologic response or BCR-ABL1 transcripts > 10% (IS) or lack of partial cytogenetic response on bone marrow cytogenetics.

‡Pathway option for second line therapy only after failure, suboptimal response, or intolerance of a second generation TKI has been used in the first line setting, or T315I mutation has been identified.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 4/28/2020 | Effective date: 8/12/2019